Advertisement

Indian Journal of Gastroenterology

, Volume 38, Issue 1, pp 61–68 | Cite as

Association between metabolic syndrome and hepatobiliary cancers: A case-control study

  • Shyam MenonEmail author
  • Ray Mathew
Original Article

Abstract

Background

The incidence of hepatobiliary cancer is steadily increasing. It is unclear if this rise is related to increasing trends in obesity, metabolic syndrome, and lifestyle changes.

Methods

A case-control study was performed using the Health Improvement Network (THIN) database. Cases with a diagnosis of liver, bile duct, and gallbladder cancers were matched in a 1:2 fashion with controls and analyzed for potential associations between hepatobiliary cancer and obesity/metabolic syndrome.

Results

Four thousand two hundred and eighty-seven patients (62% male, 38% female) with hepatobiliary cancers were matched with 8574 controls. On univariate analysis, body mass index (BMI), smoking, diabetes, alcohol consumption, ischemic heart disease, and hypertension were associated with hepatobiliary cancer. Statin use and non-smoking status had an inverse association. On multivariate analysis, BMI, diabetes, hypertension, ischemic heart disease, and insulin use were associated with the risk of hepatobiliary cancer. Statin use and non-smoking status were protective. On modeling BMI, each of diabetes and hypertension as a single covariate, there was a significant association with hepatobiliary cancer (1.59 [1.49–1.69], p < 0.001) which persisted despite adjusting for increasing age (1.006 [1005–1.006], p < 0.001) and background liver cirrhosis (1.037 [1.03–1.044], p < 0.001).

Conclusions

Obesity and metabolic syndrome are associated with the risk of hepatobiliary cancer. Statin use seems to be protective.

Keywords

Hepatobiliary cancer Hepatocellular cancer Cholangiocarcinoma Metabolic syndrome Diabetes Obesity 

Notes

Acknowledgements

None.

Funding details

This research was funded by a grant from the South Staffordshire Medical Centre Charitable Trust (The Rotha Abraham Bequest).

Compliance with ethical standards

Conflict of interest

SM, and RM declare that they have no conflict of interest.

Ethical clearance

The authors declare that the study was performed in a manner conforming to the Helsinki declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.

Disclaimer

The authors are solely responsible for the data and the content of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, or the printer/publishers are responsible for the results/ findings and content of this article.

Supplementary material

12664_2018_925_MOESM1_ESM.docx (13 kb)
ESM 1 (DOCX 13 kb)

References

  1. 1.
    Cancer Research UK. Liver cancer incidence trends over time. Cancer Research UK. 2017; cited 2017; Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/liver-cancer/incidence. Accessed 1/7/18.
  2. 2.
    SEER, Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer., in Surveillance, Epidemiology, and End Results Program. 2017; NIH: National Cancer Institute.Google Scholar
  3. 3.
    Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98:873–5.CrossRefGoogle Scholar
  4. 4.
    Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol. 2012;56:848–54.Google Scholar
  5. 5.
    Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36:1206–13.Google Scholar
  6. 6.
    Alberti KG, Zimmet P, Shaw J. Metabolic syndrome–a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.CrossRefGoogle Scholar
  7. 7.
    Simon TG, King LY, Chong DQ, et al. Diabetes, metabolic comorbidities and risk of hepatocellular carcinoma: results from two prospective cohort studies. Hepatology. 2018;67:1797–806.Google Scholar
  8. 8.
    Wu Q, He XD, Yu L, Liu W, Tao LY. The metabolic syndrome and risk factors for biliary tract cancer: a case-control study in China. Asian Pac J Cancer Prev. 2012;13:1963–9.CrossRefGoogle Scholar
  9. 9.
    THIN. THIN. The Health Improvement Network. CSD Health Research. 2015; Available from: https://www.visionhealth.co.uk/portfolio-items/the-health-improvement-network-thin/. Accessed 1/7/18.
  10. 10.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.CrossRefGoogle Scholar
  11. 11.
    Chen HF, Chen P, Li CY. Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex stratifications. Hepatology. 2010;52:155–63.CrossRefGoogle Scholar
  12. 12.
    Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656–65.CrossRefGoogle Scholar
  13. 13.
    Shan J, Shen J, Liu L, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 2012;56:1004–14.Google Scholar
  14. 14.
    McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148–55.CrossRefGoogle Scholar
  15. 15.
    Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49:851–9.Google Scholar
  16. 16.
    Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827–38.Google Scholar
  17. 17.
    Loomis AK, Kabadi S, Preiss D, et al. Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. J Clin Endocrinol Metab. 2016;101:945–52.Google Scholar
  18. 18.
    Zhang W, Sun B. Impact of age on the survival of patients with liver cancer: an analysis of 27,255 patients in the SEER database. Oncotarget. 2015;6:633–41.CrossRefGoogle Scholar
  19. 19.
    Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:881–91.CrossRefGoogle Scholar
  20. 20.
    Smith U, Gale EM. Cancer and diabetes: are we ready for prime time? Diabetologia. 2010;53:1541–4.CrossRefGoogle Scholar
  21. 21.
    Chiang GG, Abraham RT. Targeting the mTOR signalling network in cancer. Trends Mol Med. 2007;13:433–42.CrossRefGoogle Scholar
  22. 22.
    Yokomichi H, Nagai A, Hirata M, et al. Statin use and all-cause and cancer mortality: BioBank Japan cohort. J Epidemiol. 2017;27:S84–91.Google Scholar
  23. 23.
    Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett’s esophageal adenocarcinoma cells. Am J Gastroenterol. 2008;103:825–37.CrossRefGoogle Scholar
  24. 24.
    Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005;5:930–42.CrossRefGoogle Scholar
  25. 25.
    Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1654–64.CrossRefGoogle Scholar
  26. 26.
    Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut. 2010;59:1572–85.CrossRefGoogle Scholar
  27. 27.
    Bansal D, Undela K, D'Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One. 2012;7:e46691.CrossRefGoogle Scholar
  28. 28.
    Shi M, Zheng H, Nie B, Gong W, Cui X. Statin use and risk of liver cancer: an update meta-analysis. BMJ Open. 2014;4:e005399.CrossRefGoogle Scholar
  29. 29.
    Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat. 2012;135:261–9.CrossRefGoogle Scholar
  30. 30.
    Shimoyama S. Statins and gastric cancer risk. Hepatogastroenterology. 2011;58:1057–61.Google Scholar
  31. 31.
    Cui X, Xie Y, Chen M, Li J, Liao X, Shen J, et al. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control. 2012;23:1099–111.CrossRefGoogle Scholar
  32. 32.
    Peng YC, Lin CL, Hsu WY, et al. Statins are associated with a reduced risk of cholangiocarcinoma: a population-based case-control study. Br J Clin Pharmacol. 2015;80:755–61.Google Scholar

Copyright information

© Indian Society of Gastroenterology 2019

Authors and Affiliations

  1. 1.The Royal Wolverhampton NHS TrustWolverhamptonUK

Personalised recommendations